Compare prices and buy Sermorelin from 35 research peptide vendors - also called suppliers or sources. Updated daily.
A 29-amino-acid synthetic peptide matching the N-terminal 1-29 fragment of human growth hormone-releasing hormone, carried as a C-terminal amide (CAS 86168-78-7). Agonizes the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH secretion. Formerly FDA-approved as EMD Serono's Geref for diagnostic use and pediatric growth hormone deficiency, it holds no current US approval, and FDA determined the products were not withdrawn for reasons of safety or effectiveness.
For research purposes only. Not medical advice.
Sermorelin is the first 29 amino acids of human growth hormone-releasing hormone, carried as a C-terminal amide: GHRH(1-29)NH2, CAS 86168-78-7, molecular formula C149H246N44O42S. Native GHRH is 44 residues, and the 1-29 fragment is the shortest one retaining full biological activity, which is why the truncation became the drug rather than the whole hormone.
That fact organizes the category around it. CJC-1295 No DAC, also sold as Mod GRF 1-29, is this same backbone with amino-acid substitutions that resist DPP-4 cleavage, and CJC-1295 With DAC adds an albumin-binding group on top of those. Tesamorelin took the other route, keeping all 44 residues and protecting the N-terminus instead. Sermorelin is the unmodified original.
Sermorelin binds the GHRH receptor on pituitary somatotrophs and prompts the gland to release its own growth hormone in pulses, which in turn raises IGF-1. Because the signal runs through the normal secretory apparatus, the response depends on a pituitary able to answer it, which is the property that made the compound a diagnostic before it was a treatment.
Ipamorelin, GHRP-2, GHRP-6 and hexarelin reach a similar pituitary output through the ghrelin receptor GHS-R1a instead. Sermorelin, tesamorelin and both CJC-1295 rows act at the GHRH receptor. Tesamorelin vs sermorelin vs ipamorelin compares sermorelin's withdrawn approvals with tesamorelin's current one and ipamorelin's trial record.
The therapeutic evidence is small and dated. The Venezuelan Collaborative Study Group (Lanes and Carrillo, Journal of Pediatric Endocrinology, 1994) treated 16 prepubertal growth-hormone-deficient children with subcutaneous GHRH(1-29) for 12 to 24 months. Eleven were classed as responders, with growth velocity rising from 3.4 cm/yr at baseline to 6.8 cm/yr at six months and holding near 6.5 cm/yr through 24 months. Anti-GHRH antibodies appeared in 4 of those 11 by six months and 6 of 11 by twelve, without apparent effect on growth.
The diagnostic record is the stronger one. A 1999 BioDrugs review found that intravenous sermorelin produced fewer false-positive growth hormone responses in children without the deficiency than other provocative tests. A scoping review FDA commissioned from the University of Maryland Center of Excellence in Regulatory Science and Innovation, dated December 2020, excluded studies that used a brand or proprietary product and found two that met its criteria, both Italian, both using sermorelin as an experimental diagnostic for adult growth hormone deficiency.
An intranasal formulation was tried and dropped: a six-month pilot in eight prepubertal children (Acta Paediatrica, 1993) recorded growth hormone peaks falling by six weeks and further by six months, and no gain in height velocity.
Sermorelin held two separate US approvals, both EMD Serono's. NDA 19-863, Geref Diagnostic, was approved December 28, 1990 for evaluating the pituitary's capacity to secrete growth hormone. NDA 20-443, Geref, was approved September 26, 1997 for idiopathic growth hormone deficiency in children with growth failure. FDA withdrew both approvals at Serono's request, effective June 18, 2009.
The consequential document came later. Acting on a citizen petition docketed FDA-2012-P-1071, FDA determined on March 4, 2013 that neither product had been withdrawn from sale for reasons of safety or effectiveness, a finding that permits abbreviated new drug applications. Sermorelin is also absent from the list of drugs barred from compounding because they were withdrawn or removed for safety or effectiveness reasons (21 CFR 216.24).
It has still never reached a bulks list. Sermorelin acetate was nominated for compounding by outsourcing facilities under section 503B, which is what the Maryland review was commissioned to support. The nomination also covered a fixed sermorelin, GHRP-2 and GHRP-6 vial, for which the reviewers found no studies at all, and the report found no USP monograph for the substance. FDA's 503B categories list (updated March 21, 2025) holds sermorelin acetate in Category 1, bulk drug substances under evaluation. It appears in no category of FDA's 503A list (updated May 14, 2026) and on neither table of the Category 2 page, and the July 2026 advisory committee review of BPC-157 and six others did not include it.
FDA has addressed this sales channel directly. A December 10, 2024 warning letter to Xcel Research LLC named sermorelin among the products offered and held that "for research use only" labeling did not control, because the seller's own claims established a human intended use. Sermorelin is also named by the World Anti-Doping Agency under S2.2.4, prohibited at all times.
PeptideScouter indexes sermorelin vials per milligram and verifies identity against its molecular formula rather than the product title.
Not now, but it held two separate approvals. NDA 19-863, Geref Diagnostic, was approved December 28, 1990 for evaluating the pituitary's capacity to secrete growth hormone, and NDA 20-443, Geref, was approved September 26, 1997 for idiopathic growth hormone deficiency in children with growth failure. Both were held by EMD Serono, which notified FDA it was discontinuing them in 2008, and FDA withdrew both approvals effective June 18, 2009. On March 4, 2013, acting on a citizen petition docketed FDA-2012-P-1071, FDA determined that neither product had been withdrawn from sale for reasons of safety or effectiveness. Tesamorelin is the only GHRH analog holding a current US approval.
All three act at the same GHRH receptor and differ in how long they survive in circulation. Sermorelin is the unmodified GHRH(1-29) amide. CJC-1295 without DAC, also sold as Mod GRF 1-29, is that same 29-residue backbone carrying amino-acid substitutions that resist DPP-4 cleavage. CJC-1295 with DAC adds an albumin-binding group that extends its time in circulation further. Tesamorelin keeps the full 44-residue sequence and protects the N-terminus instead.
It names the salt form rather than the free base. Sermorelin is CAS 86168-78-7 with molecular formula C149H246N44O42S. The acetate is a separate substance identifier, and the two carry different masses, so a milligram figure means something slightly different depending on which was supplied. The approved Geref products handled this by declaring strength as base equivalent, for example 0.5 mg base per vial. Research listings rarely state which form the number refers to, and only a certificate of analysis settles it. Some vendors write Sermorelin Acetate on the product page while most write only Sermorelin, and the difference in the title does not reliably indicate a difference in the material.
No. Sermorelin followed a different track from most peptides in this catalog. It was never placed in Category 2 of the interim bulk drug substances policy, so it was not part of the September 2023 listings, the April 2026 removals, or the seven substances the Pharmacy Compounding Advisory Committee heard in July 2026. What did happen is that sermorelin acetate was nominated for compounding by outsourcing facilities under section 503B, and FDA commissioned the University of Maryland Center of Excellence in Regulatory Science and Innovation to review its clinical use, a report dated December 2020. The nomination also covered a fixed sermorelin, GHRP-2 and GHRP-6 vial, and the reviewers found no studies of that combination or any USP monograph for sermorelin acetate. It is not on the 503B bulks list, and FDA's 503B categories list, updated March 21, 2025, holds it in Category 1 as a substance under evaluation.
PeptideScouter computes a per-milligram price only for vials sold by weight, so a listing recorded as a nasal spray is indexed and searchable but carries no per-milligram figure, and it will not appear in per-milligram comparisons or in the lowest-price line.
Sermorelin is sold by 35 research peptide vendors indexed on PeptideScouter, with 60 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
32 of the 35 indexed vendors currently have Sermorelin in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Peppy and Me currently lists Sermorelin at $3.50/mg, the lowest listed price across 35 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.02/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 35 vendors listing Sermorelin publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.25/mg listed to $2.02/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Sermorelin ranges from $2.25/mg to $15.80/mg across 60 listings from 35 research peptide vendors, normalized to USD per milligram and refreshed daily.
35 research peptide vendors currently list Sermorelin on PeptideScouter, with 32 in stock right now. We track 60 listings across size and kit variants.
Sermorelin's CAS Registry Number is 86168-78-7. It is also sold as Sermo, SERMORLIN, Sermorelin Acetate.
